TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02529072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes. Binding of PD-1 to its ligands, programmed death-ligands 1 and 2, results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T cell responses to both foreign antigens as well as self-antigens. Nivolumab is expressed in Chinese hamster ovary cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies. The clinical study product is a sterile solution for parenteral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes. Binding of PD-1 to its ligands, programmed death-ligands 1 and 2, results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T cell responses to both foreign antigens as well as self-antigens. Nivolumab is expressed in Chinese hamster ovary cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies. The clinical study product is a sterile solution for parenteral administration.
Study: NCT01007448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexarotene
Description: Soft gelatin capsules to be taken orally with at least 6 ounces of water or other fluid either with or immediately following the evening meal (a moderate or full meal) or a nutritionally defined liquid food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexarotene
Description: Soft gelatin capsules to be taken orally with at least 6 ounces of water or other fluid either with or immediately following the evening meal (a moderate or full meal) or a nutritionally defined liquid food.
Study: NCT04496492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocotrienol
Description: Tocotrienol 200 mg orally twice a day
Study: NCT02529072

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC
Description: DCs are potent immunostimulatory cells that continuously sample the antigenic environment of the host and specifically activate cluster of differentiation 4 positive (CD4+) and cluster of differentiation 8 positive (CD8+) T-cells and B-cells. They are at the crossroads of many of the elegant networks of the immune system, and DCs represent the most promising contemporary biologic entity for realizing the promise of immunotherapy. Potent immune responses and encouraging clinical results have been seen in Phase I and II human clinical trials in systemic cancers. Numerous animal studies and the investigator's institution's humans studies have demonstrated potent antitumor responses using DC-based immunotherapy against MGs.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC
Description: DCs are potent immunostimulatory cells that continuously sample the antigenic environment of the host and specifically activate cluster of differentiation 4 positive (CD4+) and cluster of differentiation 8 positive (CD8+) T-cells and B-cells. They are at the crossroads of many of the elegant networks of the immune system, and DCs represent the most promising contemporary biologic entity for realizing the promise of immunotherapy. Potent immune responses and encouraging clinical results have been seen in Phase I and II human clinical trials in systemic cancers. Numerous animal studies and the investigator's institution's humans studies have demonstrated potent antitumor responses using DC-based immunotherapy against MGs.
Study: NCT02171416

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rilonacept

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00831337

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL3
Description: 2 times daily 450 billion live bacteria (in each saschet)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL3
Description: 2 times daily 450 billion live bacteria (in each saschet)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL3
Description: 2 times daily 450 billion live bacteria (in each saschet)
Study: NCT02743156

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI
Description: intravascular ultrasound-guided percutaneous coronary intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-guided PCI
Description: Angiography-guided percutaneous coronary intervention. This is the conventional treatment.
Study: NCT01335087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Patients with conservative treatment: (Group 2). This group will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counselling.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patients with conservative treatment: (Group 2). This group will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counselling.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous positive airway pressure
Description: Patients with CPAP treatment (Group 1): CPAP pressure titration will be performed by automated equipment before discharge. It will follow the methodology described by our group (Mass et al. Alternative Methods of titrating continuous positive airway pressure: a large multicentre study. American Journal of Respiratory and Critical Care Medicine (2004) vol. 170 (11) pp. 1218-1224). This group will also be instructed in hygienic-dietary measures recommended for all patients, standard care of cardiovascular risk factors and sleep hygiene counselling.
Study: NCT04479631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-196
Description: BRII-196 given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-196
Description: BRII-196 given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-196
Description: BRII-196 given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo given intravenously
Study: NCT04236115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Articaine 4%
Description: Articaine 4% is dental local anaesthetic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocain 3%
Description: prilocaine is dental local anaesthetic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenalin
Description: adrenaline is a vasoconstrictor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Felypressin
Description: Felypressin is a vasoconstrictor
Study: NCT02932007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine Phosphate
Description: Two tablets of study drug are to be taken on the day of study drug initiation and the next day, followed by one tablet each day for the next 12 days. Study drug to be orally administered and taken with food.
Study: NCT02684253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Study: NCT02309255

Intervention type: OTHER
Intervention: no intervention
Study: NCT03733639

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tisseel
Description: Reinforcement of esophagojejunal anastomoses after total gastrectomy with the product.

Intervention type: DEVICE
Group type: OTHER
Intervention: No Tisseel
Description: No reinforcement of esophagojejunal anastomoses after total gastrectomy
Study: NCT00479492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-866,087
Description: 1 mg of CP-866,087, administered QD for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-866,087
Description: 5 mg of CP-866,087, administered QD for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-866,087
Description: 10 mg of CP-866,087, administered QD for 84 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administered QD for 84 days
Study: NCT03637985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: resistive exercise
Description: resistive exercise by elastic band for 12 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aerobic exercise in form of treadmill walking
Description: aerobic exercise in form of treadmill walking for 12 weeks
Study: NCT03862846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REN001
Description: Once daily
Study: NCT01401582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of Dementia Care Manager
Description: Home-visits of trained Dementia Care Manager (DCM) at least monthly for 6 months. The DCM will, in close cooperation with the general practitioner, establish and include a subsidiary support system for subjects and their caregivers.
Study: NCT01809002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Processed Nerve Allograft (human)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen Nerve Cuff
Description: Bovine collagen based nerve cuff
Study: NCT04070443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: 30mg/day; 6 months. Dose adaptation procedures are planned in case of toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: 400 mg/day; at least 30 months (M7 to M36), then depending of MR4.5 . Dose adaptation procedures are planned in case of toxicity.
Study: NCT00776126

Intervention type: DEVICE
Intervention: Digital Breast Tomosynthesis Exam
Description: Digital Breast Tomosynthesis Exam consisting of single view (MLO) of each breast will be performed.
Study: NCT02528383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vagifem
Description: Women participating in the study will undergo clinical assessments, blood work and complete the quality of life questionnaire at baseline, 6 weeks and 12 weeks study time points. The following will be assessed:~1. Effect of low dose Vagifem, 10ug tablet on vaginal atrophy.~2. Effect of low dose Vagifem, 10ug tablet on sex hormones and bone health biomarkers.~3. Impact of treatment on quality of life
Study: NCT02293915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium oligo-mannurarate 900mg
Description: sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: simulant of sodium oligo-mannurarate capsule
Study: NCT03802084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vactosertib/imatinib combination
Description: Phase 1 : Imatinib 400mg QD P q28days Vactosertib 1 cohort 200mg bid (D1-5, 8-12, 15-19, 22-26)~* 1 cohort 100mg bid Phase 2 : Imatinib 400mg QD PO q28days. Vactosertib RP2D, bid (D1-5, 8-12, 15-19, 22-26)
Study: NCT02054520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HyperAcute®-Melanoma (HAM) Immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HyperAcute®-Melanoma (HAM) Immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HyperAcute®-Melanoma (HAM) Immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Study: NCT00985946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat (LBH589)
Description: Panobinostat will be taken once daily at 20 mg three times a week (every Monday, Wednesday, Friday). It will be taken as long as patients are benefiting from treatment.
Study: NCT02238665

Intervention type: DEVICE
Intervention: Endomicroscopy

Intervention type: DEVICE
Intervention: Endomicroscopy
Study: NCT02395874

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: tDCS + speech therapy
Description: Patients either receive 20min of tDCS with 2mA + speech therapy every work for 6 weeks. The anodal electrode will be placed either on the homologous speech area (TACS) in the right hemisphere or on the speech area perilesional in the left hemisphere (PACS). The cathodal electrode will be placed contralateral. Patients in group B will follow the same protocol, except for the stimulation intensity (2 mA versus 0 mA) the speech therapist will apply the tdcs according to the protocol. The tdcs machine is out of sight of the patient, so that she/he does not see, whether the machine is switched on or not. In case of sham stimulation the device will be switched on very slowly for the first 20 s and will than be set back to 0mA within the following 10 s. So that the patient will feel also the characteristic tingling under the electrodes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tDCS + speech therapy
Description: Patients either receive 20min of tDCS with 2mA + speech therapy every work for 6 weeks. The anodal electrode will be placed either on the homologous speech area (TACS) in the right hemisphere or on the speech area perilesional in the left hemisphere (PACS). The cathodal electrode will be placed contralateral. Patients in group B will follow the same protocol, except for the stimulation intensity (2 mA versus 0 mA) the speech therapist will apply the tdcs according to the protocol. The tdcs machine is out of sight of the patient, so that she/he does not see, whether the machine is switched on or not. In case of sham stimulation the device will be switched on very slowly for the first 20 s and will than be set back to 0mA within the following 10 s. So that the patient will feel also the characteristic tingling under the electrodes.
Study: NCT03975205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: To measure bioavailabity of Doxil versus Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: To measure bioavailabity of Doxil versus Doxorubicin
Study: NCT02709096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPX-01, 1% Topical Gel
Description: topical gel, applied to the forehead, cheeks, nose and chin
Study: NCT01396304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restore Calcium Alginate Dressing
Description: Wound dressing appropriate for venous leg ulcers. Dressing to be changed minimally once per week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AquaCel Ag Wound Dressing
Description: Wound dressing appropriate for venous leg ulcers. Dressing to be changed minimally once per week.
Study: NCT02858622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: bupivacaine 0.25% at a dose 2 mg/kg in the transversus abdominis plane
Study: NCT02709096

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BPX-01 Vehicle Gel
Description: topical gel, applied to the forehead, cheeks, nose and chin
Study: NCT04438577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine mucilage-ICG
Description: Lidocaine mucilage-ICG as an agent for intraoperative tumor delineation
Study: NCT02858622

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Pethidine
Description: pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine
Description: pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: perfalgan
Description: intravenous paracetamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: perfalgan
Description: intravenous paracetamol
Study: NCT02515877

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External radiotherapy + curietherapy
Description: External radiotherapy: 45 Gy in 5 weeks Curietherapy: 15Gy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vistide
Description: VISTIDE® (mg/kg) Level 1: 1mg/kg Level 2: 2,5 mg/kg Level 3: 5 mg/kg Level 4: 6,5 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC= 2,5 (Calvert formula)
Study: NCT00818649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.3mg/m\^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: 400 mg orally (po) every day on days 1-14 of a 21 day cycle
Study: NCT02926144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngoscope with video
Description: Intubation with video-laryngoscope McGrath with use of the video feature

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscope without video
Description: Endotracheal intubation with video-laryngoscope McGrath without use of the video feature
Study: NCT03513588

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet, 0 mg, 14 days, every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: tablet, 50 mg, 14 days, every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: tablet, 300 mg, 14 days, every 12 hours
Study: NCT02922309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vocal Training Via Telepractice
Description: Vocal Training Via Telepractice, delivered by integrated communication service

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vocal Training Via face-to face practice
Description: Vocal Training Via face-to face practice at medical facilities
Study: NCT02925637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FaCoT
Description: The intervention will include: functional activities, cognitive activities and strategies (pencil-pen treatment), and behavioural strategies
Study: NCT01600573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib in combination with weekly topotecan
Description: * Topotecan as an IV infusion over 30 minutes on days 1, 8, and 15 of a 28 day cycle and~* Pazopanib orally once daily continuous dosing in the following dose levels:~Phase I Trial:~Dose level -I: Topotecan weekly 3mg/m2, Pazopanib 400 mg Dose level I: Topotecan weekly 4mg/m2, Pazopanib 400 mg Dose level II: Topotecan weekly 4mg/m2, Pazopanib 600 mg Dose level III: Topotecan weekly 4mg/m2, Pazopanib 800 mg~Phase II Trial:~Phase II will either use the MTD as determined in Phase I or a lower dose if deemed necessary.
Study: NCT00572390

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oestrogen
Description: Cyclic oestrogen substitution therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oestrogen
Description: Cyclic oestrogen substitution therapy
Study: NCT02490202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SANGUINATE
Description: Two (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
Study: NCT00282204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: antenatal hypnosis + audio compact disc on hypnosis

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audio compact disc on hypnosis
Study: NCT01270971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690 Topical Solution, 5%
Description: AN2690 Topical Solution, 5%, applied once daily for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Solution Vehicle
Description: AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
Study: NCT03618654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study: NCT02077569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: Stage 1: AZD5363 480mg or placebo twice daily oral dosing for 4 and 1/2 days (9 doses) Stage 2: AZD5363 360mg or 240mg daily oral dosing for 4 and 1/2 days (9 doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: Stage 1: AZD5363 480mg or placebo twice daily oral dosing for 4 and 1/2 days (9 doses) Stage 2: AZD5363 360mg or 240mg daily oral dosing for 4 and 1/2 days (9 doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: Stage 1: AZD5363 480mg or placebo twice daily oral dosing for 4 and 1/2 days (9 doses) Stage 2: AZD5363 360mg or 240mg daily oral dosing for 4 and 1/2 days (9 doses)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD5363
Description: Stage 1: AZD5363 480mg or placebo twice daily oral dosing for 4 and 1/2 days (9 doses) Stage 2: AZD5363 360mg or 240mg daily oral dosing for 4 and 1/2 days (9 doses)
Study: NCT00002570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: 425 mg/m2 IV by bolus injection daily for 5 consecutive days q 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: 20 mg/m2 IV - number of cycles is determined by patient and physician
Study: NCT02875093

Intervention type: DRUG
Group type: OTHER
Intervention: ADI-PEG 20
Description: Investigational Medicine

Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Description: low-dose cytarabine 20 mg BID twice daily for 10 days, every 28 days
Study: NCT00188175

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: Pre-op Intensity Modulated Radiation Therapy for lower limb soft tissue sarcoma.
Study: NCT03200015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Potentially increasing the efficacy and safety of standard chemotherapy through several mechanisms
Study: NCT03188757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperglycaemic clamp
Description: 2h hyperglyceamic clamp